Telo Genomics Corp (TELO) — Cash Flow-to-Debt Ratio
Telo Genomics Corp (TELO) has a Cash Flow-to-Debt Ratio of -0.47x as of September 2025, meaning its operating cash flow of CA$-300.71K could theoretically repay 0% of its total liabilities (CA$633.60K) in one year. Check Telo Genomics Corp (TELO) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Telo Genomics Corp Cash Flow-to-Debt Ratio (2013–2025)
Historical debt coverage capacity for Telo Genomics Corp across 13 annual periods. Also explore Telo Genomics Corp asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Telo Genomics Corp (2013–2025)
Year-by-year debt coverage analysis for Telo Genomics Corp. For market capitalisation and broader financial context, see Telo Genomics Corp stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (CAD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -5.88x | CA$-2.33 Million | CA$396.32K | ▲ +10.3% |
| 2024 | -6.55x | CA$-2.46 Million | CA$375.59K | ▲ +22.1% |
| 2023 | -8.40x | CA$-2.63 Million | CA$312.87K | ▼ -7.7% |
| 2022 | -7.80x | CA$-1.79 Million | CA$230.07K | ▼ -8.5% |
| 2021 | -7.19x | CA$-1.10 Million | CA$153.66K | ▼ -152.6% |
| 2020 | -2.85x | CA$-1.12 Million | CA$393.42K | ▼ -1035.0% |
| 2019 | -0.25x | CA$-327.84K | CA$1.31 Million | ▲ +94.2% |
| 2018 | -4.31x | CA$-3.21 Million | CA$743.53K | ▲ +51.6% |
| 2017 | -8.91x | CA$-7.90 Million | CA$886.25K | ▼ -295.2% |
| 2016 | -2.26x | CA$-78.65K | CA$34.87K | ▲ +65.6% |
| 2015 | -6.55x | CA$-106.77K | CA$16.30K | ▼ -207.6% |
| 2014 | -2.13x | CA$-35.47K | CA$16.66K | ▲ +56.5% |
| 2013 | -4.90x | CA$-66.68K | CA$13.61K | — |